Skip to content
Medicamen Organics logo

Medicamen Organics

MEDIORG NSE
₹25.90 No trade today
View as Markdown
MCP
Close 2 Nov 2026 ₹25.90 −5.75 −18.2% 1Y
Start ₹31.65

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · TTM

ROCE
−10.40%
Debt to Equity
0.50
EPS (TTM)
—
Book Value
₹25.69
Market Cap
—
P/E (TTM)
—
P/B
1.01
ROE
−13.80%
Dividend Yield
0.00%
EBITDA
−₹3.70 Cr
52W High
₹32.00
52W Low
₹19.10
Volume
0

Peer Comparison

Healthcare › Pharmaceuticals

Medicamen Organics peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Medicamen Organics (this company)
₹25.90—₹39 Cr1.010.00%−13.80%−10.40%——
Median 8 companies₹1,587.7038.81₹1,25,337 Cr4.570.44%16.25%16.65%₹28,324 Cr₹3,184 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

38 Weak

Data confidence 81/100

Category scores

Quality
36
Poor
Returns, margins, earnings quality 22% weight
Valuation
41
Weak
Cheap vs sector & own history 24% weight
Growth
4
Poor
Sales & profit trajectory 9% weight
Financial Health
25
Poor
Solvency, leverage, coverage 9% weight
Momentum
53
Average
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Stock is trading at 1.04 times its book value

Weaknesses

6
  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -6.38%
  • Company has a low return on equity of 2.95% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 312 days.
  • Working capital days have increased from 147 days to 231 days

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish1711
OscillatorsBullish072
Moving AveragesStrong Bullish109

Key readings

RSI (14)
54.71
Neutral
MACD (12,26,9)
0.42
Bullish
SMA (50)
24.82
Bullish
SMA (200)
24.85
Bullish

As of

Growth Rate

From the financial statements below. 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
1Y−42.94%

Net profit

Net profit growth by window
1YTurned to loss

Operating cash flow

Operating cash flow growth by window
1YOutflow widened by ₹0.06 Cr

Operating margin· change in pp

Operating margin growth by window
1Y−33.92 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2024₹25.27 Cr
Mar 2025₹38.19 Cr
Mar 2026₹21.79 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2024₹2.62 Cr
Mar 2025₹4.05 Cr
Mar 2026−₹4.02 Cr

Half-yearly Results

₹ Cr
MEDIORG half-yearly results, ₹ crore
Particulars Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales
13.95
16.61
21.58
17.85
4.78
Expenses
11.62
13.88
17.73
14.43
11.95
Operating Profit
2.33
2.73
3.85
3.42
−7.17
OPM %
16.7%
16.44%
17.84%
19.16%
−150%
Other Income
0.01
0.04
0.05
0.06
0.02
Interest
0.36
0.22
0.29
0.33
0.38
Depreciation
0.36
0.36
0.37
0.41
0.48
PBT
1.62
2.19
3.24
2.74
−8.01
Tax %
22.84%
30.59%
21.6%
25.55%
−24.47%
Net Profit
1.26
1.51
2.54
2.04
−6.06
EPS (₹)
1.47
1.29
2.17
1.74
−4.98

Profit & Loss

₹ Cr
MEDIORG profit and loss, annual, ₹ crore
Particulars Mar 2024Mar 2025Mar 2026
Sales
25.27
38.19
21.79
Expenses
20.53
31.58
25.41
Operating Profit
4.74
6.61
−3.62
OPM %
18.76%
17.31%
−16.61%
Other Income
1.07
0.1
0.08
Interest
0.65
0.54
0.84
Depreciation
0.72
0.74
0.9
PBT
4.44
5.43
−5.28
Tax %
40.77%
25.41%
−23.86%
Net Profit
2.62
4.05
−4.02
EPS (₹)
3.05
3.46
−3.3
Div. Payout %
0%
0%
0%

Balance Sheet

₹ Cr
MEDIORG balance sheet, annual, ₹ crore
Particulars Mar 2024Mar 2025Mar 2026
Equity Capital
8.6
11.7
12.17
Reserves
6.66
18.43
16.56
Borrowings
12.66
12.35
14.29
Other Liabilities
10.52
16.73
8.61
Total Liabilities
38.44
59.21
51.63
Fixed Assets
10.35
10.13
13.37
CWIP
0.15
2.22
0.09
Investments
0
0
0
Other Assets
27.94
46.86
38.17
Total Assets
38.44
59.21
51.63

Cash Flow

₹ Cr
MEDIORG cash flow, annual, ₹ crore
Particulars Mar 2024Mar 2025Mar 2026
Operating
−3.66
−4.54
−4.6
Investing
−0.34
−2.35
−1.72
Financing
4.01
10.47
3.48
Net Cash Flow
0.01
3.58
−2.83
Free Cash Flow
−4.01
−6.99
−6.34
CFO/OP
−73
−67
124

Ratios

MEDIORG financial ratios, annual
Particulars Mar 2024Mar 2025Mar 2026
Debtor Days
241
247
312
Inventory Days
244
228
468
Days Payable
282
358
247
Cash Conversion Cycle
204
118
532
Working Capital Days
74.24
135
231
ROCE %
—
16.88%
−10.45%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Medicamen Organics insights

60 extracted metrics across FY22–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 54.89%
  • Others 23.79%
  • Public 21.26%
  • FIIs 0.05%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Medicamen Organics

What does Medicamen Organics Ltd do?
Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage
Where is Medicamen Organics Ltd (MEDIORG) listed?
Medicamen Organics Ltd trades as MEDIORG on the NSE.
Which sector does Medicamen Organics Ltd belong to?
Medicamen Organics Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Medicamen Organics Ltd?
Over the last 52 weeks Medicamen Organics Ltd has traded between ₹19.1 and ₹32 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Medicamen Organics Ltd?
Medicamen Organics Ltd reported a return on equity of -13.80%. Its debt-to-equity ratio is 0.50.

Company Information

Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of pharmaceutical dosages including generic dosage

Website medicamenorganics.com
Listed 28 Jun 2024
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/MEDIORG.md for Medicamen Organics Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month